SG170739A1 - Iap bir domain binding compounds - Google Patents
Iap bir domain binding compoundsInfo
- Publication number
- SG170739A1 SG170739A1 SG201101952-8A SG2011019528A SG170739A1 SG 170739 A1 SG170739 A1 SG 170739A1 SG 2011019528 A SG2011019528 A SG 2011019528A SG 170739 A1 SG170739 A1 SG 170739A1
- Authority
- SG
- Singapore
- Prior art keywords
- binding compounds
- domain binding
- bir domain
- iap bir
- iap
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1761—Apoptosis related proteins, e.g. Apoptotic protease-activating factor-1 (APAF-1), Bax, Bax-inhibitory protein(s)(BI; bax-I), Myeloid cell leukemia associated protein (MCL-1), Inhibitor of apoptosis [IAP] or Bcl-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrrole Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78252306P | 2006-03-16 | 2006-03-16 | |
US87699406P | 2006-12-26 | 2006-12-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG170739A1 true SG170739A1 (en) | 2011-05-30 |
Family
ID=38509005
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG201101952-8A SG170739A1 (en) | 2006-03-16 | 2007-03-16 | Iap bir domain binding compounds |
Country Status (15)
Country | Link |
---|---|
US (5) | US7579320B2 (no) |
EP (1) | EP2004600A4 (no) |
JP (1) | JP5419468B2 (no) |
KR (1) | KR101446907B1 (no) |
AU (1) | AU2007224932B2 (no) |
BR (1) | BRPI0709610A2 (no) |
CA (1) | CA2581960C (no) |
IL (1) | IL193951A (no) |
MX (1) | MX2008011837A (no) |
NO (1) | NO20083868L (no) |
NZ (1) | NZ571577A (no) |
PH (1) | PH12014502420B1 (no) |
SG (1) | SG170739A1 (no) |
TW (2) | TWI543988B (no) |
WO (1) | WO2007104162A1 (no) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1773766B1 (en) | 2004-07-15 | 2014-04-02 | Tetralogic Pharmaceuticals Corporation | Iap binding compounds |
KR101278732B1 (ko) | 2004-12-20 | 2013-07-09 | 제넨테크, 인크. | Iap의 피롤리딘 억제제 |
ES2456671T3 (es) | 2005-02-25 | 2014-04-23 | Tetralogic Pharmaceuticals Corporation | Inhibidores diméricos de IAP |
JP4954983B2 (ja) | 2005-05-18 | 2012-06-20 | ファーマサイエンス・インコーポレイテッド | Birドメイン結合化合物 |
US20100256046A1 (en) * | 2009-04-03 | 2010-10-07 | Tetralogic Pharmaceuticals Corporation | Treatment of proliferative disorders |
KR20080067357A (ko) | 2005-10-25 | 2008-07-18 | 에게라 쎄라퓨틱스 인코포레이티드 | Iap bir 도메인 결합 화합물 |
JP5155184B2 (ja) | 2005-12-19 | 2013-02-27 | ジェネンテック, インコーポレイテッド | Iapのインヒビター |
TWI543988B (zh) * | 2006-03-16 | 2016-08-01 | 科學製藥股份有限公司 | 結合於細胞凋亡抑制蛋白(iap)之桿狀病毒iap重複序列(bir)區域之化合物 |
US7807699B2 (en) * | 2006-03-21 | 2010-10-05 | Joyant Pharmaceuticals, Inc. | Dimeric pyrrolidine amide-containing small molecule apoptosis promoters |
CN101535300B (zh) | 2006-05-16 | 2014-05-28 | 埃格拉医疗公司 | Iap bir域结合化合物 |
KR20090041391A (ko) * | 2006-07-24 | 2009-04-28 | 테트랄로직 파마슈티칼스 | 이량체성 iap 길항제 |
US8143426B2 (en) * | 2006-07-24 | 2012-03-27 | Tetralogic Pharmaceuticals Corporation | IAP inhibitors |
US20100144650A1 (en) * | 2006-07-24 | 2010-06-10 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
MX2009010667A (es) * | 2007-04-12 | 2010-02-24 | Joyant Pharmaceuticals Inc | Dimeros y trimeros mimeticos de smac utiles como agentes anti-cancer. |
BRPI0809867A2 (pt) * | 2007-04-30 | 2014-09-30 | Genentech Inc | Composto, método de indução da apoptose em uma célula, método de sensibilização de uma célula para um sinal apoptótico, método para inibir a ligação de uma proteína iap a uma proteína caspase e métodos |
WO2008137930A1 (en) * | 2007-05-07 | 2008-11-13 | Tetralogic Pharmaceuticals Corp. | TNFα GENE EXPRESSION AS A BIOMARKER OF SENSITIVITY TO ANTAGONISTS OF INHIBITOR OF APOPTOSIS PROTEINS |
WO2008144925A1 (en) * | 2007-05-30 | 2008-12-04 | Aegera Therapeutics Inc. | Iap bir domain binding compounds |
EP2276761B1 (en) | 2008-04-23 | 2015-07-29 | Rigel Pharmaceuticals, Inc. | Carboxamide compounds for the treatment of metabolic disorders |
WO2009136290A1 (en) * | 2008-05-05 | 2009-11-12 | Aegera Therapeutics, Inc. | Functionalized pyrrolidines and use thereof as iap inhibitors |
AU2009261919A1 (en) * | 2008-06-27 | 2009-12-30 | Pharmascience Inc. | Bridged secondary amines and use thereof as IAP BIR domain binding compounds |
WO2010017035A2 (en) * | 2008-08-02 | 2010-02-11 | Genentech, Inc. | Inhibitors of iap |
US20120009141A1 (en) * | 2008-08-07 | 2012-01-12 | Pharmascience Inc. | Functionalized pyrrolidines and use thereof as iap inhibitors |
WO2010031171A1 (en) * | 2008-09-19 | 2010-03-25 | Aegera Therapeutics, Inc. | Iap bir domain binding compounds |
US20100317593A1 (en) * | 2009-06-12 | 2010-12-16 | Astrazeneca Ab | 2,3-dihydro-1h-indene compounds |
US8283372B2 (en) | 2009-07-02 | 2012-10-09 | Tetralogic Pharmaceuticals Corp. | 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic |
US8551955B2 (en) * | 2009-10-28 | 2013-10-08 | Joyant Pharmaceuticals, Inc. | Dimeric Smac mimetics |
SG182724A1 (en) | 2010-02-12 | 2012-08-30 | Pharmascience Inc | Iap bir domain binding compounds |
UY33236A (es) | 2010-02-25 | 2011-09-30 | Novartis Ag | Inhibidores dimericos de las iap |
WO2012052758A1 (en) * | 2010-10-22 | 2012-04-26 | Astrazeneca Ab | Response biomarkers for iap antagonists in human cancers |
UY33794A (es) | 2010-12-13 | 2012-07-31 | Novartis Ag | Inhibidores diméricos de las iap |
WO2015196091A1 (en) | 2014-06-20 | 2015-12-23 | Reform Biologics, Llc | Viscosity-reducing excipient compounds for protein formulations |
US10478498B2 (en) | 2014-06-20 | 2019-11-19 | Reform Biologics, Llc | Excipient compounds for biopolymer formulations |
US11357857B2 (en) | 2014-06-20 | 2022-06-14 | Comera Life Sciences, Inc. | Excipient compounds for protein processing |
CA2916970A1 (en) * | 2016-01-08 | 2017-07-08 | Pharmascience Inc. | A smac mimetic compound for use in the treatment of proliferative diseases |
AU2018308116A1 (en) * | 2017-07-25 | 2020-02-13 | Hepagene Therapeutics (HK) Limited | Dimeric peptide inhibitors of apoptosis proteins |
CN117130035A (zh) * | 2017-08-18 | 2023-11-28 | 南京中硼联康医疗科技有限公司 | 生物剂量计及具有其的中子捕获治疗系统 |
JP2021523092A (ja) * | 2018-03-21 | 2021-09-02 | ピラマル・ファーマ・リミテッドPiramal Pharma Limited | アルファ−(ジアリールメチル)アルキルアミンの改良された不斉合成 |
WO2020027225A1 (ja) | 2018-07-31 | 2020-02-06 | ファイメクス株式会社 | 複素環化合物 |
EP3886909A4 (en) * | 2018-11-29 | 2023-03-29 | Comera Life Sciences, Inc. | ADDITOR COMPOUNDS FOR PROTEIN PROCESSING |
EP3946607A1 (en) | 2019-04-05 | 2022-02-09 | Hepagene Therapeutics (HK) Limited | Bivalent antagonists of inhibitors of apoptosis proteins |
WO2020223403A1 (en) * | 2019-04-29 | 2020-11-05 | The Regents Of The University Of California | Anticancer smac derivatives |
WO2021020585A1 (ja) | 2019-07-31 | 2021-02-04 | ファイメクス株式会社 | 複素環化合物 |
CN114980883A (zh) | 2020-01-20 | 2022-08-30 | 阿斯利康(瑞典)有限公司 | 用于治疗癌症的表皮生长因子受体酪氨酸激酶抑制剂 |
CA3179181A1 (en) | 2021-03-15 | 2022-09-22 | Maze Therapeutics, Inc. | Inhibitors of glycogen synthase 1 (gys1) and methods of use thereof |
WO2023127331A1 (ja) * | 2021-12-27 | 2023-07-06 | 株式会社トクヤマ | ペプチド製造方法、保護基の除去方法、除去剤、及びベンジル化合物 |
JP7260725B1 (ja) * | 2021-12-27 | 2023-04-18 | 株式会社トクヤマ | ペプチド製造方法、保護基の除去方法、及び除去剤 |
Family Cites Families (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US69812A (en) * | 1867-10-15 | Improved refrigerator | ||
US25347A (en) * | 1859-09-06 | Improvement | ||
US93429A (en) * | 1869-08-10 | Improvement in flasks for vulcanizing rubber plates for setting teeth | ||
US258581A (en) * | 1882-05-30 | husset | ||
US32437A (en) * | 1861-05-28 | Improvement in steam-plows | ||
US93428A (en) * | 1869-08-10 | Improvement in spurs for excelsior-machines | ||
US207525A (en) * | 1878-08-27 | Improvement in car-coupling draw-bars | ||
US180828A (en) * | 1876-08-08 | Improvement in horse-powers | ||
US194741A (en) * | 1877-08-28 | Improvement in circular looms | ||
US89896A (en) * | 1869-05-11 | Improvement in bee-hive | ||
US219140A (en) * | 1879-09-02 | Improvement in the art of ornamenting metallic foils | ||
US211627A (en) * | 1879-01-28 | Improvement in perforating-stamps | ||
JPH0680077B2 (ja) | 1985-02-08 | 1994-10-12 | サントリー株式会社 | プロリンエンドペプチダ−ゼインヒビタ−活性を有する新規ペプチド化合物 |
JPH04208299A (ja) | 1990-11-30 | 1992-07-29 | Ajinomoto Co Inc | プロリルエンドペプチターゼ阻害ペプチド |
US5817667A (en) * | 1991-04-17 | 1998-10-06 | University Of Georgia Research Foudation | Compounds and methods for the treatment of cancer |
US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
AUPN727595A0 (en) * | 1995-12-22 | 1996-01-18 | Walter And Eliza Hall Institute Of Medical Research, The | Therapeutic compositions |
JP4208299B2 (ja) | 1998-08-19 | 2009-01-14 | 東レ株式会社 | 金属板貼合わせ成形加工用ポリエステルフィルム |
US6110691A (en) * | 2000-01-06 | 2000-08-29 | Board Of Regents, The University Of Texas System | Activators of caspases |
US6608026B1 (en) * | 2000-08-23 | 2003-08-19 | Board Of Regents, The University Of Texas System | Apoptotic compounds |
AU2001293189A1 (en) | 2000-09-29 | 2002-04-08 | Trustees Of Princeton University | Compositions and methods for regulating apoptosis |
US6992063B2 (en) * | 2000-09-29 | 2006-01-31 | The Trustees Of Princeton University | Compositions and method for regulating apoptosis |
WO2002030959A2 (en) | 2000-10-13 | 2002-04-18 | Abbott Laboratories | Peptides derived from smac (diablo) and methods of use therefor |
WO2002100327A2 (en) * | 2001-05-16 | 2002-12-19 | Antexpharma, Inc. | Substituted 1-benzazepines and derivatives thereof |
CA2449168A1 (en) | 2001-05-31 | 2002-12-05 | The Trustees Of Princeton University | Iap binding peptides and assays for identifying compounds that bind iap |
AU2002314165B2 (en) * | 2001-06-19 | 2008-02-21 | Altana Pharma Ag | Tryptase inhibitors |
US20060258581A1 (en) | 2001-11-21 | 2006-11-16 | Reed John C | Methods and composition for derepressions of IAP-inhibited caspase |
EP1495124A2 (en) | 2002-04-17 | 2005-01-12 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Smac-peptides as therapeutics against cancer and autoimmune diseases |
EP1519918A1 (en) | 2002-07-02 | 2005-04-06 | Novartis AG | Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap) |
EP1578777B1 (en) | 2002-07-15 | 2008-11-26 | The Trustees of Princeton University | Iap binding compounds |
FR2844271A1 (fr) * | 2002-09-09 | 2004-03-12 | Oreal | Derives bis-paraphenylenediamine a groupement pyrrolidinyle et utilisation de ces derives pour la coloration de fibres keratiniques |
ATE481092T1 (de) * | 2002-11-27 | 2010-10-15 | Irm Llc | Verfahren und zusammensetzungen zur apoptoseinduktion in krebszellen |
WO2004066958A2 (en) | 2003-01-30 | 2004-08-12 | The Trustees Of Princeton University | Caspase-9:bir3 domain of xiap complexes and methods of use |
US7067274B2 (en) * | 2003-11-13 | 2006-06-27 | Genentech, Inc. | Compositions and methods for the screening pro-apoptotic compounds |
CA2553871A1 (en) | 2004-01-16 | 2005-08-04 | The Regents Of The University Of Michigan | Smac peptidomimetics and the uses thereof |
JP2007520522A (ja) | 2004-02-05 | 2007-07-26 | ノバルティス アクチエンゲゼルシャフト | (a)DNAトポイソメラーゼ阻害剤および(b)IAP阻害剤の組み合わせ剤 |
CN1926118A (zh) * | 2004-03-01 | 2007-03-07 | 德克萨斯大学董事会 | 二聚的小分子细胞凋亡增强剂 |
CA2558615C (en) | 2004-03-23 | 2013-10-29 | Genentech, Inc. | Azabicyclo-octane inhibitors of iap |
RS52545B (en) | 2004-04-07 | 2013-04-30 | Novartis Ag | INHIBITORI PROTEIN APOPTOZE (IAP) |
CA2570321C (en) * | 2004-07-02 | 2013-10-08 | Genentech, Inc. | Inhibitors of iap |
US7674787B2 (en) | 2004-07-09 | 2010-03-09 | The Regents Of The University Of Michigan | Conformationally constrained Smac mimetics and the uses thereof |
AU2005271831A1 (en) | 2004-07-12 | 2006-02-16 | Idun Pharmaceuticals, Inc. | Tetrapeptide analogs |
EP1773766B1 (en) | 2004-07-15 | 2014-04-02 | Tetralogic Pharmaceuticals Corporation | Iap binding compounds |
KR101278732B1 (ko) | 2004-12-20 | 2013-07-09 | 제넨테크, 인크. | Iap의 피롤리딘 억제제 |
ES2456671T3 (es) * | 2005-02-25 | 2014-04-23 | Tetralogic Pharmaceuticals Corporation | Inhibidores diméricos de IAP |
US20070003535A1 (en) | 2005-03-17 | 2007-01-04 | Reed John C | Methods and compositions for derepression of IAP-inhibited caspase |
DE102005017116A1 (de) | 2005-04-13 | 2006-10-26 | Novartis Ag | Hemmstoffe für Inhibitoren von Apoptose Proteinen (IAP) |
JP4954983B2 (ja) | 2005-05-18 | 2012-06-20 | ファーマサイエンス・インコーポレイテッド | Birドメイン結合化合物 |
WO2006128455A2 (en) | 2005-05-25 | 2006-12-07 | 2Curex Aps | Compounds modifying apoptosis |
CN101193908B (zh) | 2005-06-08 | 2012-04-11 | 诺瓦提斯公司 | 有机化合物 |
US20070042428A1 (en) * | 2005-08-09 | 2007-02-22 | Stacy Springs | Treatment of proliferative disorders |
KR20080067357A (ko) | 2005-10-25 | 2008-07-18 | 에게라 쎄라퓨틱스 인코포레이티드 | Iap bir 도메인 결합 화합물 |
JP5155184B2 (ja) | 2005-12-19 | 2013-02-27 | ジェネンテック, インコーポレイテッド | Iapのインヒビター |
JP5227805B2 (ja) | 2005-12-20 | 2013-07-03 | ノバルティス アーゲー | Iap阻害剤とタキサン7の組合せ剤 |
WO2007101347A1 (en) | 2006-03-07 | 2007-09-13 | Aegera Therapeutics Inc. | Bir domain binding compounds |
TWI543988B (zh) | 2006-03-16 | 2016-08-01 | 科學製藥股份有限公司 | 結合於細胞凋亡抑制蛋白(iap)之桿狀病毒iap重複序列(bir)區域之化合物 |
US7807699B2 (en) | 2006-03-21 | 2010-10-05 | Joyant Pharmaceuticals, Inc. | Dimeric pyrrolidine amide-containing small molecule apoptosis promoters |
KR101071516B1 (ko) | 2006-05-05 | 2011-10-10 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | 2가 smac 모방체 및 그의 용도 |
CN101535300B (zh) | 2006-05-16 | 2014-05-28 | 埃格拉医疗公司 | Iap bir域结合化合物 |
US20100056495A1 (en) | 2006-07-24 | 2010-03-04 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
WO2008014240A2 (en) | 2006-07-24 | 2008-01-31 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
WO2008014238A2 (en) | 2006-07-24 | 2008-01-31 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
US8143426B2 (en) | 2006-07-24 | 2012-03-27 | Tetralogic Pharmaceuticals Corporation | IAP inhibitors |
US20100144650A1 (en) | 2006-07-24 | 2010-06-10 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
KR20090041391A (ko) | 2006-07-24 | 2009-04-28 | 테트랄로직 파마슈티칼스 | 이량체성 iap 길항제 |
PE20080951A1 (es) | 2006-08-02 | 2008-09-11 | Novartis Ag | DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS |
MX2009003834A (es) | 2006-10-12 | 2009-04-22 | Novartis Ag | Derivados de pirrolidina como inhibidores de iap. |
CA2665838A1 (en) | 2006-10-19 | 2008-05-15 | Novartis Ag | Organic compounds |
MX2009005621A (es) | 2006-11-28 | 2009-06-12 | Novartis Ag | Combinacion de inhibidores de iap e inhibidores de flt3. |
KR20090083412A (ko) | 2006-11-28 | 2009-08-03 | 노파르티스 아게 | 급성 골수성 백혈병의 치료를 위한 iap 억제제의 용도 |
JP2010512322A (ja) | 2006-12-07 | 2010-04-22 | ノバルティス アーゲー | 有機化合物 |
NZ577150A (en) | 2006-12-19 | 2012-04-27 | Genentech Inc | Imidazopyridine inhibitors of iap |
MX2009010667A (es) | 2007-04-12 | 2010-02-24 | Joyant Pharmaceuticals Inc | Dimeros y trimeros mimeticos de smac utiles como agentes anti-cancer. |
EA017797B1 (ru) | 2007-04-13 | 2013-03-29 | Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган | Бициклические диазомиметики smac, способы их получения, их применения, содержащие их фармацевтические композиции и набор, содержащий указанные композиции |
BRPI0809867A2 (pt) | 2007-04-30 | 2014-09-30 | Genentech Inc | Composto, método de indução da apoptose em uma célula, método de sensibilização de uma célula para um sinal apoptótico, método para inibir a ligação de uma proteína iap a uma proteína caspase e métodos |
WO2008144925A1 (en) | 2007-05-30 | 2008-12-04 | Aegera Therapeutics Inc. | Iap bir domain binding compounds |
EP2058312A1 (en) | 2007-11-09 | 2009-05-13 | Universita' degli Studi di Milano | SMAC mimetic compounds as apoptosis inducers |
-
2007
- 2007-03-15 TW TW103145747A patent/TWI543988B/zh not_active IP Right Cessation
- 2007-03-15 TW TW096108935A patent/TWI504597B/zh not_active IP Right Cessation
- 2007-03-16 AU AU2007224932A patent/AU2007224932B2/en not_active Ceased
- 2007-03-16 NZ NZ571577A patent/NZ571577A/en not_active IP Right Cessation
- 2007-03-16 MX MX2008011837A patent/MX2008011837A/es active IP Right Grant
- 2007-03-16 CA CA2581960A patent/CA2581960C/en not_active Expired - Fee Related
- 2007-03-16 JP JP2008558611A patent/JP5419468B2/ja not_active Expired - Fee Related
- 2007-03-16 WO PCT/CA2007/000428 patent/WO2007104162A1/en active Application Filing
- 2007-03-16 EP EP07710756A patent/EP2004600A4/en not_active Withdrawn
- 2007-03-16 SG SG201101952-8A patent/SG170739A1/en unknown
- 2007-03-16 BR BRPI0709610-0A patent/BRPI0709610A2/pt not_active IP Right Cessation
- 2007-03-16 US US11/723,044 patent/US7579320B2/en not_active Expired - Fee Related
- 2007-03-16 KR KR1020087025218A patent/KR101446907B1/ko not_active IP Right Cessation
- 2007-11-01 US US11/979,280 patent/US7645741B2/en not_active Expired - Fee Related
-
2008
- 2008-09-07 IL IL193951A patent/IL193951A/en not_active IP Right Cessation
- 2008-09-09 NO NO20083868A patent/NO20083868L/no not_active Application Discontinuation
-
2009
- 2009-11-17 US US12/619,979 patent/US20100221261A1/en not_active Abandoned
-
2012
- 2012-11-08 US US13/672,637 patent/US8765681B2/en not_active Expired - Fee Related
-
2014
- 2014-05-23 US US14/285,841 patent/US9365614B2/en not_active Expired - Fee Related
- 2014-10-28 PH PH12014502420A patent/PH12014502420B1/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20080207525A1 (en) | 2008-08-28 |
NO20083868L (no) | 2008-11-06 |
JP2009529544A (ja) | 2009-08-20 |
IL193951A (en) | 2015-09-24 |
US9365614B2 (en) | 2016-06-14 |
PH12014502420A1 (en) | 2015-11-16 |
US20130071411A1 (en) | 2013-03-21 |
TW201538520A (zh) | 2015-10-16 |
RU2008140935A (ru) | 2010-04-27 |
MX2008011837A (es) | 2009-02-10 |
US20100221261A1 (en) | 2010-09-02 |
US20140336134A1 (en) | 2014-11-13 |
KR101446907B1 (ko) | 2014-10-06 |
EP2004600A1 (en) | 2008-12-24 |
AU2007224932A1 (en) | 2007-09-20 |
US7645741B2 (en) | 2010-01-12 |
US7579320B2 (en) | 2009-08-25 |
JP5419468B2 (ja) | 2014-02-19 |
TWI504597B (zh) | 2015-10-21 |
TWI543988B (zh) | 2016-08-01 |
CA2581960A1 (en) | 2007-09-16 |
TW200800961A (en) | 2008-01-01 |
BRPI0709610A2 (pt) | 2011-07-19 |
PH12014502420B1 (en) | 2015-11-16 |
KR20080112304A (ko) | 2008-12-24 |
WO2007104162A1 (en) | 2007-09-20 |
AU2007224932B2 (en) | 2013-05-23 |
US8765681B2 (en) | 2014-07-01 |
US20080069812A1 (en) | 2008-03-20 |
EP2004600A4 (en) | 2012-05-02 |
NZ571577A (en) | 2011-09-30 |
CA2581960C (en) | 2015-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12014502420B1 (en) | Iap bir domain binding compound | |
MY159563A (en) | Iap bir domain binding compounds | |
HRP20130653T1 (en) | Pyrrole compounds | |
TW200744586A (en) | Therapeutic compounds | |
TW200833686A (en) | Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors | |
GEP20135785B (en) | Pyrrolopyrimidine compounds as cdk inhibitors | |
MX2009010595A (es) | Derivados de pirrolopirimidina. | |
MX2009011199A (es) | Derivados de pirimidina. | |
PH12015501585A1 (en) | Manufacturing process for pyrimidine derivatives | |
TN2011000053A1 (en) | Organic compounds | |
MX2008010931A (es) | Quinolonas utiles como inhibidores de sintasa de oxido nitrico inducibles. | |
HK1087632A1 (en) | 4-anilino-quinazoline derivatives as antiproliferative agents | |
WO2008057775A3 (en) | Heterocyclic amide compounds useful as kinase inhibitors | |
WO2008108378A3 (en) | Bicyclic oxomorpholine derivative | |
MX340870B (es) | Compuestos de unión del dominio de repetición de inhibidores de proteínas de apoptosis de baculovirus. | |
MX2009007713A (es) | Derivados de piridazina, procedimientos para su preparacion y su uso como fungicidas. | |
NZ579928A (en) | Fluorinated derivatives of deferiprone | |
MX2009003257A (es) | Procedimiento para la sintesis de derivados de fenoxi diaminopirimidina. | |
IL198901A0 (en) | Pyrimidine derivatives and multiple myeloma | |
TW200613292A (en) | Benzothiazolium compounds | |
MX2009011059A (es) | Aminopirimidinas utiles como inhibidores de cinasas. | |
MX2010009276A (es) | Pirrolopirimidincarboxamidas. | |
MY160882A (en) | Biocidal composition and method | |
EA201100696A1 (ru) | 1-(арилсульфонил)-4-(пиперазин-1-ил)-1h-бензимидазолы в качестве лигандов 5-гидрокситриптамина-6 | |
TW200740766A (en) | Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6-ligands |